Antonini Angelo, Odin Per, Pahwa Rajesh, Aldred Jason, Alobaidi Ali, Jalundhwala Yash J, Kukreja Pavnit, Bergmann Lars, Inguva Sushmitha, Bao Yanjun, Chaudhuri K Ray
Parkinson and Movement Disorders Unit, Center for Rare Neurological Diseases (ERN-RND), Department of Neurosciences, University of Padova, Padua, Italy.
Division of Neurology, Department of Clinical Sciences, Skåne University Hospital, Lund University, Lund, Sweden.
Adv Ther. 2021 Jun;38(6):2854-2890. doi: 10.1007/s12325-021-01747-1. Epub 2021 May 20.
Levodopa/carbidopa intestinal gel (LCIG; carbidopa/levodopa enteral suspension) has been widely used and studied for the treatment of motor fluctuations in levodopa-responsive patients with advanced Parkinson's disease (PD) when other treatments have not given satisfactory results. Reduction in 'off'-time is a common primary endpoint in studies of LCIG, and it is important to assess the durability of this response. This systematic literature review was conducted to qualitatively summarise the data on the long-term effects of LCIG therapy on 'off'-time.
Studies were identified by searching PubMed, EMBASE and Ovid on 30 September 2019. Studies were included if they reported on patients with PD, had a sample size of ≥ 10, LCIG was an active intervention and 'off'-time was reported for ≥ 12 months after initiation of LCIG treatment. Randomised clinical trials, retrospective and prospective observational studies, and other interventional studies were included for selection. Data were collected on: 'off'-time (at pre-specified time periods and the end of follow-up), study characteristics, Unified Parkinson's Disease Rating Scale (UPDRS) II, III and IV total scores, dyskinesia duration, quality of life scores, non-motor symptoms and safety outcomes.
Twenty-seven studies were included in this review. The improvement in 'off'-time observed shortly after initiating LCIG was maintained and was statistically significant at the end of follow-up in 24 of 27 studies. 'Off'-time was reduced from baseline to end of follow-up by 38-84% and was accompanied by a clinically meaningful improvement in quality of life. Stratified analysis of 'off'-time demonstrated mean relative reductions of 47-82% at 3-6 months and up to 83% reduction at 3-5 years of follow-up. Most studies reported significant improvements in activities of daily living and motor complications. Most frequent adverse events were related to the procedure or the device.
In one of the largest qualitative syntheses of published LCIG studies, LCIG treatment was observed to provide a durable effect in reducing 'off'-time.
Video Abstract.
左旋多巴/卡比多巴肠凝胶(LCIG;卡比多巴/左旋多巴肠内混悬液)已被广泛应用于左旋多巴反应性晚期帕金森病(PD)患者运动波动的治疗,尤其适用于其他治疗效果不佳的情况。减少“关”期是LCIG研究中常见的主要终点,评估这种反应的持续性很重要。本系统文献综述旨在定性总结LCIG治疗对“关”期长期影响的数据。
2019年9月30日通过检索PubMed、EMBASE和Ovid来确定研究。纳入的研究需报告PD患者情况,样本量≥10,LCIG为活性干预措施且在LCIG治疗开始后报告“关”期≥12个月。随机临床试验、回顾性和前瞻性观察性研究以及其他干预性研究均纳入筛选范围。收集的数据包括:“关”期(在预先指定的时间段和随访结束时)、研究特征、统一帕金森病评定量表(UPDRS)II、III和IV总分、异动症持续时间、生活质量评分、非运动症状和安全性结果。
本综述纳入了27项研究。在开始LCIG治疗后不久观察到的“关”期改善得以维持,27项研究中有24项在随访结束时具有统计学意义。“关”期从基线到随访结束减少了38% - 84%,同时生活质量在临床上有显著改善。“关”期的分层分析显示,在3 - 6个月时平均相对减少47% - 82%,在3 - 5年随访时减少高达83%。大多数研究报告日常生活活动和运动并发症有显著改善。最常见的不良事件与操作过程或设备有关。
在已发表的LCIG研究的最大规模定性综合分析之一中,观察到LCIG治疗在减少“关”期方面具有持久效果。
视频摘要。